CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy

BMC Surgery

Table 2 Recurrence rates in patients with positive tumor markers

tumor markers	stage I and II GC	patients with recurrence	stage III GC	patients with recurrence
preoperative(%)^a
CEA(+)	48	2(4.2)	90	35(38.9)*
CA19-9(+)	27	2(7.4)	67	32(47.8)*
CA72-4(+)	45	4(8.9)	60	21(35.0)*
postoperative(%)^a
CEA(+)	37	1(2.7)	74	36(48.6)*
CA19-9(+)	10	2(20.0)	42	28(66.7)*
CA72-4(+)	23	2(8.7)	38	24(63.2)*

GC: Gastric Cancer; CEA(+): CEA > 5 ng/mL; CA19-9(+): CA19-9 > 35 U/mL; CA72-4(+): CA72-4 > 6.9 U/mL; ^aPearson chi-squared test or Fisher’s exact test; compared with the stage I and II GC group, *P < 0.05

ISSN: 1471-2482